Open Access

Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases

  • Authors:
    • Hiroshi Takeyama
    • Tomoko Wakasa
    • Keisuke Inoue
    • Kotaro Kitani
    • Masanori Tsujie
    • Takafumi Ogawa
    • Masao Yukawa
    • Yoshio Ohta
    • Masatoshi Inoue
  • View Affiliations

  • Published online on: May 10, 2018     https://doi.org/10.3892/mco.2018.1623
  • Pages:3-10
  • Copyright: © Takeyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

In patients with colorectal liver metastases (CRLM), predictive markers for response to preoperative chemotherapy are lacking. The aim of the present study was to evaluate the expression of thymidylate synthase (TS) and excision repair cross‑complementation group 1 (ERCC1) as predictive markers in CRLM. A total of 24 patients with CRLM were included in this study. Tumor response was evaluated using the tumor regression grade (TRG) and Response Evaluation Criteria in Solid Tumors (RECIST) methods. TS and ERCC1 expression in paired CRLM and primary lesions were assessed by immunohistochemistry. We analyzed correlations between i) the response to preoperative chemotherapy evaluated by TRG and RECIST, ii) TS and ERCC1 expression and the response evaluated by TRG and RESICT, and iii) TS and ERCC1 expression in matched pairs of primary tumor and CRLM. The preoperative chemotherapy response evaluated by TRG and RECIST was significantly associated (P=0.0005). The response based on RECIST criteria and TRG was significantly associated with TS expression in the primary tumor (P=0.0272, and P=0.0137, respectively). No correlations were detected between marker expression in the primary tumor and in CRLM for either TS or ERCC1 (P=0.371 and P=1.00, respectively). Our data suggested that TS expression in the primary tumor is a predictive marker of preoperative chemotherapy response in CRLM based on both TRG and RECIST methods.

Related Articles

Journal Cover

July 2018
Volume 9 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Takeyama, H., Wakasa, T., Inoue, K., Kitani, K., Tsujie, M., Ogawa, T. ... Inoue, M. (2018). Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases. Molecular and Clinical Oncology, 9, 3-10. https://doi.org/10.3892/mco.2018.1623
MLA
Takeyama, H., Wakasa, T., Inoue, K., Kitani, K., Tsujie, M., Ogawa, T., Yukawa, M., Ohta, Y., Inoue, M."Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases". Molecular and Clinical Oncology 9.1 (2018): 3-10.
Chicago
Takeyama, H., Wakasa, T., Inoue, K., Kitani, K., Tsujie, M., Ogawa, T., Yukawa, M., Ohta, Y., Inoue, M."Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases". Molecular and Clinical Oncology 9, no. 1 (2018): 3-10. https://doi.org/10.3892/mco.2018.1623